Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC

While poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) have achieved specific clinical benefits in a subset of pancreatic ductal adenocarcinoma (PDAC) patients, the potential role of the PARPi niraparib in PDAC necessitates further exploration. In this study, we demonstrated that Ni...

Full description

Bibliographic Details

Published in:	Translational Oncology
Main Authors:	Zehui Yao, Huihui Zhang, Kewei Huang, Guizhong Huang, Pu Xi, Lingmin Jiang, Dailei Qin, Fan Chen, Shengping Li, Ran Wei
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Subjects:	Pancreatic ductal adenocarcinoma Niraparib Autophagy Gemcitabine-resistance
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523324003334